Clinical Data Integrity: Clean US FDA Inspection No Guarantee That DoJ Won’t Investigate

Justice department has investigative tools that can uncover fraudulent activity even when a clinical site passes inspection, DoJ’s Clint Narver says; in deciding whether to self-report possible clinical trial fraud to FDA and DoJ, sponsors should consider that other companies would benefit from knowing this information about a particular site or investigator.  

Escalator
Drug sponsors need to have clear processes in place for escalating concerns about clinical data fraud. • Source: Shutterstock

More from Clinical Trials

More from R&D